SRP-3D is under clinical development by South Rampart Pharma and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SRP-3D’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SRP-3D is under development as an oral formulation for the treatment of neuropathic pain, fever, chronic pain, diabetic neuropathic pain, chemotherapy neuropathic pain and other neuropathic pain syndromes, as an ophthalmic formulation for ocular pain, as an intravenous formulation for acute pain and intravenous formulation for treatment of fever. It is an analog of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide.
South Rampart Pharma overview
South Rampart Pharma is a developer of drugs for treating acute, chronic, and neuropathic pain. The company is headquartered in New Orleans, Louisiana, the US.
For a complete picture of SRP-3D’s drug-specific PTSR and LoA scores, buy the report here.